Cortexyme has announced that its GAIN Phase 2/3 #clinicaltrial failed to meet its co-primary endpoints in people with mild to moderate #Alzheimer’s disease.
ya, nothing wrong if people wanna sell or buy. and there is no such thing the share price will only 1 way up, sure will up down up down one lah. important thing is you know the stock well and believe in its future. if you bet it right the share price will sure up in future
Malaysia casino operator Genting plans to sell some of its Miami real estate, and is seeking more than US$1 billion (S$1.38 billion) as it looks to focus on other investment opportunities such as New York.
1) sell some of its Miami real estate, and is seeking more than US$1 billion (S$1.38 billion) as it looks to focus on other investment opportunities such as New York. 2) Future Plan - To List Genting Las Vegas Hotel and Casino - More than US$4.5 billions. 3) Paying back all the loan and Liabilities. 4) Debt free and Cash Rich. 5) To pay more dividend.
Genting Berhad has the business that wil generate income continuously… from casino, recreation resorts/ hotels, creating new treatment for Alzheimer disease, producting oil palm, last but not least oil and gas industry… huge business empire with growth momentum!
TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions.
This is the first time any treatment has produced evidence of sustained improvement over the individual’s own pre-treatment baseline lasting 18 months at an early clinically detectable stage of AD, and stabilization of disease progression at more severe stages. The results in AD confirm published findings from two earlier HMTM Phase 3 trials. The availability of an accessible oral treatment which does not require expensive monitoring over routine clinical care opens up an opportunity to intervene before the onset of the cognitive and functional decline that lead to loss of independence. “Tau pathology of the disease is now recognized as an important target for treatment, and it is encouraging that cognitive improvement is seen at such an early stage of the disease with a drug targeting Tau. The field has focused mainly on amyloid as a target for early intervention. Our data are consistent with the evidence that Tau pathology begins at least 20 years before clinical symptoms appear and is a viable first-line target for treatment.”
The safety profile seen in LUCIDITY remains strong and consistent with earlier published HMTM trial data. There were no treatment-related serious adverse events or evidence of amyloid related imaging abnormalities (ARIA).
— Professor Claude Wischik, Executive Chairman and co-founder of TauRx
There are not many iconic shares for foreign funds to buy… No doubt, Genting Berhad is one of the list not to miss by the funds… I bet you that Foreign funds are slowly scooping Genting Berhad at such rock bottom price! You may mark my words… May all of us Huat Huat Huat with Genting Berhad!
Remember Anwar was jailed for 11 years and waited for 24 years to be Prime Minister of Malaysia. Due to his perseverance, numerous sweats and hardships, finally he sworn in as PM 10 of Malaysia on 24 November 2022.
Personally looking at Genting Berhad business, starting from 1. casinos (run 24 hours a day), 2. resorts (run 24 hours a day), 3. palm oil business (run 12 hours a day harvesting sun energy), 4. oil and gas (run 24 hours a day), 5. TauRx (run 12 hours a day)…
Most importantly, all are generating profits even when you are sleeping/ exercising/ resting/ eating/ drinking etc…
That's what I don't like about these drug process, mid 2023 for 24 month review. Hopefully the approval criteria don't need to wait for 36, 48, 60 month review
Very very promising TauRX …..2023 is the year when it gets regulatory approval. Approval is sought in many markets and chances are high that it will be available soon. As as we hear about the first approval, and inside information suggests that this could be early 2023, the price of Genting will be rerated. The value of Genting investment is not based on market value. There will be significant rerating. In addition to this sale of property in Miami will also book in significant gains ….so 2023 will definitely be the year when share price breaks away! Market will hopefully move ahead of actual events.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
James_Bond
3,486 posts
Posted by James_Bond > 2022-11-29 13:02 | Report Abuse
Sparing 2million to buy Genting Berhad… Collecting mode… Cheers!